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At The George Washington University School of Medicine and Health Sciences, we are
fortunate to have exceptional research opportunities available to us in diverse and exciting
fields. Some of the projects medical students have undertaken involve basic science research, others involve clinical research and health policy, and several include international
medical experiences. In recent years, the development of Track Programs and the number
of fellowships offered by the Office of Student Opportunities have dramatically increased
these worthwhile opportunities.
By establishing a scientific medical student journal named Fusion, which we hope will
be published annually, we aim to capture the excitement of the many research-related
endeavors of our peers and give members of the broader scientific and medical community
an opportunity to learn about the comprehensive and multi-layered experiences of GW
medical students. We are hopeful that Fusion will entice current and future students to
engage in the many research opportunities available and share their experiences.
Responses to our call for submissions to Fusion exceeded our expectations. We received
22 submissions, demonstrating the pressing need and desire of our peers for an opportunity to write about and share their work. Our decision to solicit submissions from members of both the Classes of 2009 and 2010 acknowledges our understanding that the
number of GW students who enter with previous research experience is rapidly increasing
and that the work they have undertaken is valuable to us. Members of the Student Editorial Board, consisting of elected officers of the William Beaumont Research Honor Society,
reviewed each submission selected for publication. Responsibility for the content of each
article, however, remains with its author.
We thank W. Scott Schroth, MD, MPH, and James Scott, MD, FACEP, in the Office
of the Deans; Anne Hirshfield, PhD, in the Office of Research; Linda Dent, Thom
Kohout, Debbie Goldstein and Abby Vogel in the Office of Marketing and Communications; and Rachel Mazzotta and Chistopher D’Avella in the Office of Student Opportunities for providing guidance, generous support and resources to make this publication possible.
Thank you,
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from the dean’s office. . .

Many would say that the opportunity to practice medicine is, by itself, a sufficiently noble and rewarding career.
However, the real beauty of the field is that it offers one so
many possible avenues to contribute to the health of individuals and society. Not only are
there a multitude of different
clinical specialties, but also, one
may contribute through research,
education, administration and
community service. Most importantly, all of these contributions
can be carried forward as scholarly
disciplines, adding not only to the
health of people, but also to the
advancement of medicine as a
field.
This new journal, conceived
and carried forward by students
dedicated to scholarly investigation, is a testament to the array of
talents and interests among our
diverse and accomplished student body. I commend both
the students who have organized this journal and all of
those who have contributed their work to its pages.
When Dean James Scott was appointed several years
ago, he articulated an important vision for the education
of our medical students. Building on a solid foundation
of medical education in basic and clinical sciences, he
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wanted to enable students to pursue their unique interests
by taking advantage of the many opportunities afforded by
the School of Medicine and Health Sciences and through
our close relationships with the School of Public Health
and Health Services, other schools in
the University and organizations
throughout the District of Columbia.
Indeed, GW exists in a landscape that
is unique and rich with opportunity.
Over the past several years, the work
of many has supported this vision.
The Beaumont Research Society, the
Office of Student Opportunities, the
Office of International Medical Programs and the Program in Medical
Humanities now form a unique infrastructure to support the scholarly
interests of medical students
throughout their four years at GW.
The contributions to Fusion are testament to the success of this effort, and
to the curiosity and hard work of our students.

W. Scott Schroth, MD, MPH
Senior Associate Dean for Academic Affairs
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from the research office. . .

It is with great pleasure that I introduce to you the inaugural issue
of Fusion, a compilation of articles
submitted by some of GW’s most
promising medical students.
These students are members of
GW’s William Beaumont Medical
Research Honor Society. The Beaumont Society was established at
the GW School of Medicine in
1935 to promote student research
and there are many accomplished
scientists throughout the country
who list membership in the society
amongst their honors.
The articles in this book describe various short term research
projects performed by Beaumont
students during the summer of 2006. Most of these students were supported by stipends from the WT Gill Endowment which has provided our medical students with
the resources to experience what biomedical research entails. In 2006, we were fortunate to be able to provide
more opportunities to students due to the additional stipends made available through generous gifts from an
anonymous donor, as well as from Dr. Jane Klein and Dr.
Robert D. Rosenberg (Medicine ’61), a graduate of our
Medical School who has had a distinguished career in biomedical research. We are grateful for these generous donations that enable us to provide intensive short-term research experiences for our students. The opportunity to
experience research first-hand is invaluable at this stage in
these students’ education as they decide whether a career
as a clinician/researcher is the right path for them. In
2006, we were fortunate to be able to provide more opportunities to students due to the additional stipends
made available through generous gifts from an anonymous
donor, Drs. Gerald (Medicine ’63) and Audrey Lazarus;
Christopher Barley, MD ’93; Keshav Narain, MD ’92;
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Charles Walkoff, MD ’59; Robert
Rosenberg, MD ’61; and Jane Klein.
Fusion is a testament, not only to
the creativity and accomplishments of
our medical students, but also to the
creativity and commitment of the student leaders of the Beaumont Society.
I want to especially recognize Andrew
Lerner, President of the Beaumont Society, and Rahul Araya, the Society’s
Research Journal Chair. These students conceived of the idea to produce
this issue and worked tirelessly to make
it happen. Remarkably, they managed
to find time for this extracurricular
activity while managing the demands
of the second-year curriculum. Recognition also goes to the GW staff members who contributed to this effort, especially Linda Dent,
Medical Center Communications Director, who gave generously of her time and valuable guidance, and Abby Vogel,
who worked with the students with the editing and layout, along with Debbie Goldstein and Thomas Kohout,
all from the Communications and Marketing Office.
Thanks also to Sarah Hassaine, Health Research Information
Support Specialist, for her editing and suggestions.
As you flip through the proceeding pages and see firsthand the varied interests of GW’s students, we hope that
you will appreciate all the hard work that our students
have put forward. I’m sure their mentors would agree that
these students have given back more than they received;
having them in our labs and clinics greatly enriches our
own growth and research endeavors.

Anne Hirshfield, PhD
Associate Vice President
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health policy issues. . .
Smoke-Free Children’
Children’ss National Medical Center Campus

Rahul Arya, MSII,
Community Health Track
Advisor: Dana Best, MD, MPH
Children’s National Medical Center
Washington, DC
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Hydrogen cyanide—used in
chemical weapons. Arsenic—used in pesticides.
Benzene—found in gasoline.
Polonium-210—radioactive
and toxic. What do these
substances have in common?
They are among the thousands of carcinogenic and toxic
substances found
in tobacco smoke.
Tobacco use is
the leading preventable cause of
death in the
United States, and
the health consequences extend
beyond smokers to nonsmokers involuntarily exposed to secondhand smoke
(SHS).1 In the U.S., SHS has
been linked to at least
53,000 non-smoker deaths
each year,2,3 including 3,400
deaths from lung cancer,
43,000 from cardiac-related
illnesses and 430 from Sudden Infant Death Syndrome
(SIDS).4
These statistics make it
imperative that hospitals be
smoke free. In 1991, The
Joint Commission on Accreditation of Health Organizations (JCAHO) announced a tobacco control
standard for accredited
American hospitals that
mandated that hospital buildings be smoke free by De-

cember 31, 1993.5 Ninetysix percent of hospitals met
this JCAHO tobacco control
standard.5
A number of hospitals
throughout the country have
taken this smoke-free standard further and made their

entire campuses smoke free,
meaning that no smoking is
allowed in campus buildings
or on the surrounding
grounds and ramps.
The major factor behind
going smoke free was recognition of the fact that
healthcare facilities must
promote smoking cessation
and serve as role models.
The smoking policy at the
Mayo Medical Center in
Minnesota recognizes its
obligation to its patients and
the public to strongly assert
the risks of tobacco use by
establishing a smoke-free
campus.6 The University of
Michigan Health System
implemented a campus-wide
smoke-free policy in February 1999 to “help people

take control of their health”
and “to create healthy communities.”7 Advocates of
campus-wide smoking bans
argue that providing a place
to smoke does not support a
healthcare institution’s goal
and mission to provide a
healthier environment for
patients, visitors and employees.7
At Children’s National
Medical Center (CNMC) in
Washington, DC, the official
smoking policy prohibits
smoking on hospital premises, including all buildings
and parking areas. The designated smoking area is a
booth located outside the
Emergency Room entrance.
However, there are no clear
guidelines on tobacco use on
other parts of the campus,
nearby grounds, ramps and
adjacent sidewalks. As a
result, people frequently
smoke in CNMC’s
entranceways and on the
campus grounds, despite the
presence of conspicuous
“No Smoking” signs.
A straightforward campus-wide smoke-free policy,
if implemented at CNMC,
would provide a healthier
environment for patients,
employees and visitors, and
would further the hospital’s
mission statement. It could
also promote smoking cessation among the hospital em-
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ployees and send a strong
message to the community
about the harmful effects of
smoking. To further this
message, research is currently underway at CNMC
to assess employee, patient
and visitor attitudes toward
making the entire campus
smoke free. The results of
the study will be used to
develop a proposal to introduce a campus-wide smoking ban at CNMC.
CNMC is currently
ranked ninth among all pediatric hospitals nationwide by
US News and World Report.8

It is high time that a nationally recognized healthcare
institution with a mission “to
excel in care, advocacy, research and institution”
implement a campus-wide
smoke-free policy.

REFERENCES:
1. Centers for Disease Control
and Prevention. State-specific
prevalence of current cigarette
smoking among adults United States, 2003. MMWR
Morb Mortal Wkly Rep.
2004;53(44):1035-1037.
2. CDC. Smoking and Tobacco
Control Monograph No. 10.

http://
cancercontrol.cancer.gov/tcrb/
monographs/10/. Accessed
July 27, 2006.
3. Fichtenberg C, Glantz S.
Effect of smoke-free workplaces on smoking behaviour:
systematic review. British
Medical Journal. 2002;
325(7357):188.
4. USDHHS. Health Consequences of Involuntary Exposure
to Tobacco Smoke: A Report of
the Surgeon General. Atlanta
2006.
5. Longo D, Feldman M, Kruse
R, Brownson R, Petroski G,
Hewett J. Implementing
smoking bans in American

hospitals: results of a national
survey. Tob Control. 1998;
7(1):47-55.
6. Mayo Clinic Smoking Policy.
http://jeny.ipro.org/
attachment.php?attachmentid=536.
Accessed June 13, 2006.
7. Barnes D, Hanauer P, Slade J,
Bero L, Glantz S. Environmental Tobacco Smoke: The
Brown and Williamson Documents. JAMA. 1995;274(3):
248-253.
8. U.S. News and World Report.
Best Hospitals 2006, Pediatrics. http://www.usnews.com/
usnews/health/best-hospitals/
rankings/specreppedi.htm.
Accessed June 11, 2006.

Speeding for a Solution:
Ambulance Diversion and the ED Crowding Crisis

Rachel Kastl-Casey, MSII,
Health Policy Track
Advisors: Bruce Siegel, MD, MPH, and
Marcia Wilson, MBA, PhD (candidate)
Department of Health Policy,
The George Washington University
Medical Center
Washington, DC
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Emergency Departments
(EDs) are in a state of crisis
as they struggle to manage a
surging demand with insufficient resources. Emergency
room visits have risen an
average of 3.7 percent over
the last five years,1 making
EDs the primary source of
healthcare for many Americans.2
Consequently, EDs have
become crowded and unable
to readily care for such a
large patient population. It is
therefore necessary to find a
way to moderate demand
and improve the quality of
patient healthcare.3
One method hospitals
currently use to relieve
crowding and limit patient
outflow is through ambulance diversion. In the event
that an ED feels it cannot
safely accept additional patients, it can request that

ambulances be diverted to an
alternate hospital.
Although ambulance diversion was initially intended
to be a temporary solution,
it has become an increas-

ingly routine response to the
escalating ED crowding crisis. However, widespread
use of this measure has had
unintended consequences
that compound, rather than
relieve, the problem of
crowding. The increased
practice of diverting ambulances to less crowded hospitals has led to increased patient transport time, in-

creased paramedic turnaround time and decreased
ambulance availability.4 Efforts are now being made to
reduce diversion as a response to ED overcrowding.
Establishing policy and
regulations for managing
diversion has proven to be a
significant challenge. Without sufficient federal attention on the issue, responsibility has fallen to states and
local communities. In an
investigation of major initiatives, three states and three
local communities stood out
in their efforts to manage
ambulance diversion. Although they differed in management style, each sought to
find some standardized fashion to manage and decrease
diversion.
Massachusetts, New York
and Arizona produced written guidelines to direct hos-
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pitals regarding how to
implement a diversion reduction plan. Massachusetts
mandated several detailed
plans and procedures for
hospitals to follow, while
New York and Arizona created guidelines that gave
hospitals the autonomy to
develop their own specific
protocols. Massachusetts
provided the most direction
and subsequently displayed
the most evidence of improvement in ambulance
diversion reduction statewide.
San Diego, Sacramento
and Syracuse substantially
reduced ambulance diversion
through voluntary hospital
and county collaboration.
San Diego and Sacramento
produced detailed protocols

that focused on hospital operational improvements to
reduce crowding and hence
decrease the need for diversion, while Syracuse put
minimal restrictions on hospitals, allowing them to develop their own strategies.
These community collaborations showed significantly greater reduction in
diversion hours than those
reported in statewide initiatives. With smaller areas and
fewer stakeholders (e.g.,
hospitals), communities were
able to closely monitor and
maintain progress through
consistent commitment and
cooperation.
Ambulance diversion is a
flawed solution to ED
crowding that requires urgent attention on a national

level. Without a national
standard in place, some
states and communities have
worked to create their own
protocols, resulting in improvements as well as inconsistencies throughout the
country. The time has come
for federal guidance in creating a unified, proven standard for states and local
communities to use. The
federal government must
take responsibility for this
problem by developing national evidence-based diversion reduction policies and
protocols. Implementing
proven solutions through a
national effort will help states
and communities achieve
consistency and increase the
likelihood of nationwide
success.
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Impact of Medicare Part D on Prescription Drug
Coverage for Patients with Chronic Conditions

Shakti Nayar, MSII, Health Policy Track
Advisor: Janice Blanchard, MD
Emergency Department,
The George Washington University
Medical Center
Washington, DC
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President Bush enacted the
Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 in December 2003. At its core
was Medicare Part D, a voluntary benefit intended to
decrease prescription drug
costs for Medicare enrollees.
Starting in 2004, Medicare enrollees could purchase
Medicare drug discount
cards to buy prescriptions at
a discount. This program
ended on January 1, 2006,
when the full Medicare Part
D drug benefit began for
those who enrolled by November 15, 2005.
Rather than having one
uniform plan for all Medi-

care Part D enrollees, there
were a number of plans provided by various private
companies that differed in
types of cost sharing and
drug formularies. Medicare
beneficiaries had to determine which of the many
plans was best for them and
enroll in Part D independently.1 Some enrollees were
previously enrolled in drug
plans that provided more
cost savings than the Part D
plans to which they
switched.2,3 Determining
whether to enroll in Part D
and choosing a specific plan
may have been confusing to
many Medicare beneficiaries. 4

Because the emergency
department is a critical access site, it was a useful location to study prescription
drug coverage as part of
care. Study participants were
recruited from patients presenting to The George Wash-
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Figure 1. Respondents with lower
incomes were more likely to use
Medicare drug discount cards preimplementation and Medicare Part D
post-implementation. Respondents
with higher incomes were more likely
to use private insurance or self-pay
pre-implementation. The percentage
of respondents that used private
insurance increased to 50 percent
post-implementation.
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ington University Hospital Emergency Department with chronic
conditions, regardless
of their primary complaint. The study population included insured
(private/HMO), Medicaid, Medicare and
uninsured patients.
Participants were given
a primary survey with
basic demographic
questions and questions to evaluate barriers to care, including
access to prescription
medications. Univariate
analysis was used to assess
the relationship between the
outcomes of interest and
main demographic variables.
A total of 862 surveys
were collected between
March 1, 2004 and August
1, 2006, and a pilot crosssectional analysis of the
Medicare subpopulation was
performed. There were 152
Medicare respondents preimplementation of Part D
and 38 respondents postimplementation. Methods of
payment for prescriptions
were compared by income
and out-of-pocket (OOP)
costs.
Comparing insurance
type to income, respondents
with a salary of less than
$14,000 reported using
Medicare drug discount
cards pre-implementation of
Part D more than any other
type of payment (Figure 1).
After implementation, the
majority of respondents in
the same income bracket
reported using Medicare
Part D to obtain prescription
medications than other payment method. The majority
of respondents with a salary
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Improving Medical School Curricula:
Examining Basic Science Lectures and Assessments

Marc Lener, MSII, Medical Education Track
Advisors: James Brawer, PhD, and
Yvonne Steinert, PhD
McGill University Centre for Medical
Education
Montreal, Quebec, Canada
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I entered medical school
interested in pursuing a career in both medicine and
medical education. As a participant in the Medical Education Track, I have been
able to pursue this professional goal.
This past summer, I
crossed the border into Canadian territory and had the
opportunity to work on two
separate projects focused on
two major areas of basic
science medical curriculum:
basic science lectures and
the quality of basic science
assessments. This article
provides a brief history of
medical school curriculum
and a synopsis of the two
projects on which I worked
at McGill University in
Montreal, Quebec, Canada.
Since the publication of
the Flexner Report in 1910,1
medical schools in the
United States and Canada
have divided their curricula
into separate biomedical
science and clinical educations. The basic science curriculum is didactic—requiring students to sit through
lectures organized by course
directors and deans and then
later assessed by in-house
examinations to hold students accountable for the
information presented to
them. These two processes
govern how medical educators organize their curricula
and dictate how students
learn and prepare to succeed
in medical school courses.
Throughout the last century,

the traditional views of
medical curricula have been
challenged.
About 30 years ago,
McMaster University in
Hamilton, Ontario, Canada
developed a problem-based
learning curriculum that has
evolved and been adopted by

many American and Canadian medical schools. It was
met with relatively insignificant success; medical schools
are now attempting to implement an organ-system approach to their basic science
curricula. This approach to
learning medicine investigates each organ system by
integrating normal structure
and function with pathological processes and pharmacological intervention. Lastly,
lectures have become less

didactic and more student
centered, and examinations
emphasize clinical application and analysis. Unfortunately, this reform has been
slow moving and narrow
reaching.
At McGill University, my
first project focused on how
students perceive basic
science lectures and
what value
they place on
lectures in
their medical
education.
Jim Brawer,
PhD, a
McGill medical educator
and a medical
education
researcher,
was inspired
to pursue this
project after
a recent mandate by the
Licensing
Committee
on Medical Education to
reduce lecturing hours. The
value of lecture has been a
controversial topic in higher
education and has been
negatively reviewed by the
popular press and various
educational journals. However, never before have research studies asked medical
students their opinions about
the value of lecture and the
role that it plays in learning
medicine. Through questionnaires, medical students
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were asked their opinions
about basic science lectures.
Responses were categorized into themes and rated
based on frequency. Of 150
students in the class, 50
completed questionnaires
were submitted. Students’
views on lecture were generally positive, and the following themes were uncovered.
Lectures:
• Provided focus or emphasis on the material
• Provided an overview or
“big picture” of course
• Explained or resolved
difficulties in the notes or
other readings
• Reinforced learning by
hearing and seeing the
information
• Provided depth, insights
and examples not in readings
• Allowed for a time-efficient way to learn
• Provided exposure to and
interaction with experts
or role models
• Encouraged structure and
discipline
• Soothed anxiety about the
material.
Limited to one medical
school and only one-third of
one class of students, the
results of this preliminary
study showed that students
value lecture in ways that
cannot be substituted by any
other teaching methodology.
However, if the lecture is
valuable, one might wonder
how other teaching methodologies can complement the
value that is inherent to the
lecture. A research paper on
this topic is in preparation.
My second project focused on the quality of medical school examinations.
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medical school MCQs is
While this project was not
undoubtedly dependent on
part of my original summer
the level of questions that are
project goals, my curiosity
asked. However, a common
and passion for methodoloproblem with writing ingies in medical testing prodhouse examinations is that
ded me to initiate several
many MCQs tend to be
discussions with Centre diknowledge-based questions,
rector Yvonne Steinert, PhD,
therefore
about a popromoting
tential
memorization
project. With
Results
of
this
prewithout anaher support
lytical thinkand
liminary study
ing.3 Because
mentorship, I
showed that stustarted to
students tend
dents value lecture
formulate a
to tailor their
literature
studies apin ways that canreview on
propriately to
not be substituted
medical
meet the exby
any
other
teachschool examipectations of
nations. I
their assessing methodology.
contacted
ments,
experts in the
MCQs can
field of medical test developplay a critical role in learnment and became inspired to
ing.4 Medical school MCQs
present my findings to the
must go beyond knowledge
faculty of The George Washand offer a greater proporington University School of
tion of higher-level questions
Medicine and Health Scithat emphasize application of
ences (SMHS). Among the
knowledge, analysis, integragroup of test experts, I was
tion and synthesis. The
able to communicate with
USMLE Step examinations
Susan Case, PhD, and
are well constructed and
David Swanson, PhD, psyreviewed such that they offer
chometricians and inventors
a variety of question types
of the United States Medical
and test a wide range of cogLicensing Examination
nitive skills.3 Thus, medical
(USMLE) Step examinations
faculty must learn from the
(previously the National
USMLE and construct exBoard of Medical Examiners
aminations that allow stu1-3). They provided impordents to learn at a higher
tant focus points and wistaxonomic level. Furtherdom from their experiences
more, if low-quality examiworking with medical school
nations are administered to
faculty on test development.
students, then students will
The following is an abstract
be less prepared to perform
from my analysis:2
well on other assessments of
higher-order thinking, like
Medical school faculty in
the USMLE.
U.S. medical schools design
Jozefowicz et al’s paper
in-house assessments that
includes an excerpt from the
often consist of 50 or more
2002 report on in-house
multiple-choice questions
medical school examina(MCQs). The quality of

tions.5 Within their discussion, the authors state, “Faculty responsible for writing
examinations should be
trained; writing good examination questions is a skill
that can be learned…a committee should review, critique and approve the content and format of the final
draft of the examination.”5
I hope to share what I
have learned from the wealth
of existing medical education
research with the medical
faculty and deans at the GW
SMHS to help implement
changes to basic science
assessments.
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clinical practice. . .
Equivalency of Cancer Detection in Analog
Mammography versus Digitized Analog Mammography

Vivek Patil, MSII, Research Track
Advisor: Rachel F. Brem, MD
Department of Radiology,
The George Washington University
Medical Center
Washington, DC
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Screen-film mammography,
the traditional x-ray and film
variety used for decades, is
the gold standard for breast
cancer screening. However,
sensitivity for breast cancer
detection is only 85 percent,
and therefore, 15 percent of
screened cancers are overlooked.1
Despite the imperfect nature of current
mammography, it has
been credited with
reducing the mortality
rate of breast cancer.2
Yearly mammograms
after age 50 are important because prognosis is best when the
cancer is detected
early.
The goal of this
study was to establish
equivalency between traditional screen-film mammography and digitized analog
mammography. A digitized
analog mammogram is a
traditional screen-film mammogram that has been digitized for evaluation on a
softcopy workstation, or
computer with a high-resolution monitor specifically
designed for radiology applications.
Since there are advantages
to using the digital medium

over film, this study was
both necessary and timely.
One benefit of digitized
mammography is that image
settings, such as contrast and
zoom, can be adjusted.
Other advantages include the
ability to store and transmit
images in an electronic format. This prevents losing

would be able to experience
the benefits of digital images
without spending the large
sums of money required for
conversion to full-field digital
mammography. Full-field
digital mammography allows
images to be captured directly on the computer without the intermediate film
Vivek Patil
studies an
analog
mammogram
on traditional
x-ray film.

films and facilitates consultation with other radiologists
who may be off site.
In this study conducted at
The George Washington
University Medical Center,
the equivalency of analog
mammography and digitized
analog mammography was
assessed with respect to cancer detection rates. If both
viewing conditions, analog
and digitized analog, detected cancer at the same
rates, Radiology departments

step required for digitized
analog mammography.
Approval from the Institutional Review Board was
obtained in March 2006 for
this study involving 200 patients. Informed consent was
waived because this study
was retrospective and only
used medical records.
Mammograms were obtained from the Breast Care
Center at The George Washington University Hospital in
Washington, DC. Cases
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were digitized with
TotalLook (Icad, Inc.,
Nashua, NH) and viewed on
a softcopy workstation
(SecurView, Hologic, Inc.,
Bedford, MA), complete
with two high-resolution 21inch grayscale monitors.
Films were digitized and
a multi-reader multi-case
receiver operating characteristic (ROC) study was conducted to assess equivalency
of analog and digitized analog mammograms for cancer
detection. Each radiologist
reader was required to read
the same 200 cases on traditional film and softcopy
workstation. Each radiologist
chose the lighting conditions
and a magnifying glass was
provided. All identifiable
patient information was hidden except for age. In order

to prevent radiologists from
remembering specific
mammograms, a minimum
of four weeks elapsed between the two reading conditions and the sequence in
which the cases were presented was randomized. Five
readers and 200 cases were
used to obtain sufficient
statistical power.
To determine whether a
radiologist detected a cancer
correctly, the Breast Imaging
Reporting and Data System
(BIRADS) developed by the
American College of Radiology was used. The BIRADS
score and location were collected for each case.
BIRADS scores range from
one (negative finding) to five
(highly suggestive of malignancy). True positives were
defined as an accurate

BIRADS assignment with
accompanying accurate lesion localization.
Fifty analog-detected and
biopsy-proven cancer cases
were included in the study.
Only malignant lesions that
were ductal carcinoma in
situ (DCIS) or invasive carcinoma one centimeter or
less were used in the study.
These small cancer sizes
were used because equivalency between the two reading conditions would be obvious if large lesions were
used. To dilute the study set,
150 non-cancer cases were
included.
The results of the study
are not yet available because
the study is still underway.
The results of the study may
have a profound impact on
the field of mammography

for years to come. In addition, valuable experience was
gained planning and conducting this research, which
led to a strong interest in a
career in Radiology—a field
that utilizes modern technology and clinical knowledge.

REFERENCES:
1. Rosenberg E, Hunt W,
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therapy on screening mammographic sensitivity and cancer
stage at diagnosis: review of
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209:511-518.
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R. Digital Mammography.
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Benefit of Intra-Articular Corticosteroid Injection
Under Fluoroscopic Guidance for Subtalar Arthritis in
Juvenile Idiopathic Arthritis

Sandy Cho, MSI, Research Track
Advisor: Anne Marie Cahill, MD
The Children’s Hospital of Philadelphia
Philadelphia, PA
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Nearly 300,000
children in the
United States
have a form of
arthritis. The
most prevalent
form of juvenile
arthritis is juvenile idiopathic
arthritis (JIA),
which affects approximately
50,000 children in the U.S.
Symptoms can be acute,
lasting for weeks to months,
or they can be chronic, lasting for months to years.

Periods of quiescence
may be punctuated by bouts
of recurrence, in some cases
throughout a lifetime. Even
if the disease “burns out,”

which frequently
occurs before
adulthood, resulting joint changes
may cause permanent disfigurement, pain and/
or disability.
Children with
acute JIA have
swollen, painful
joints that may
be stiff and difficult to move.
Chronic inflammation can
cause significant morbidity,
including spontaneous joint
fusion or debilitating pain,

13

requiring arthrodesis,1,2 the
surgical fusion of a joint
with the goal of pain relief.
Chronic pain, spontaneous
subtalar fusion or arthrodesis
can lead to an altered foot
movement, or gait, with
undue stresses placed on
other weight-bearing joints,
resulting in further morbidity.1,3
Treating inflammation in the
acute phase
should reduce
synovial thickening and alterations
in the architecture
of the cartilage
and underlying
bone, better preserving joint function throughout
life.
Intra-articular
corticosteroid
injections are
frequently used
and a proven
therapy for a variety of joints
in children with JIA.4,5 Although involvement of the
subtalar joint in the foot is
common in JIA, intra-articular treatment of this joint is
rarely attempted due to its
anatomic complexity and
resulting technical difficulty
in accessing the joint without image guidance (Figure
1).
The purpose of this study
was to use fluoroscopically
guided intra-articular
subtalar steroid injection in
JIA patients with acute
symptoms to more accurately access the joint and
relieve pain and increase
foot movement.
Fluoroscopically guided
subtalar joint injections were
performed in 38 children

14

(mean age 6.7 years). Medical records were reviewed
retrospectively and clinical
improvement was evaluated
by the degree of eversion
and inversion foot movements.
Image-guided subtalar
joint injections were safely

subtalar symptoms were
more likely to improve than
patients treated more than
one year after subtalar symptoms were first diagnosed
(p=0.04).
This pilot work supports
an image-guided approach to
early treatment of joints af-

73-80.
2. Wu W, Huang P, Lin C, Chen
W, Huang K, Cheng Y. Lower
extremity kinematics and
kinetics during level walking
and stair climbing in subjects
with triple arthrodesis or
subtalar fusion. Gait Posture
2005;21(3):263-270.

Figure 1. Diagram of foot showing the
complexity of the location of the
subtalar (Talocalcaneal) joint. Intraarticular treatment of this joint is
rarely attempted due to the technical
difficulty in accessing the joint
(Courtesy of Drake RL, Vogl, W,
Mitchell A. Moore K, Dalley A. Gray’s
Anatomy for Students. Philadelphia:
Elsevier; 2005).

and successfully achieved
with positive confirmation of
intra-articular steroid delivery in 100 percent of the JIA
patients. Improved range of
motion was seen in 34 of 38
subjects (89 percent) and 44
percent of the subjects returned to a normal range of
motion. Regardless of the
elapsed time between injection and examination, clinical improvement was defined
as increased foot eversion
and inversion at the followup visit. Resolution was defined clinically as normal
foot eversion and inversion
without clinical subtalar
symptoms. The mean duration of improvement was
found to be 1.1±0.9 years.
Notably, patients treated
within one year of onset of

fected by inflammatory arthritis, such as the subtalar
joint that is difficult to access by palpation alone.
Once subtalar involvement is
identified, prompt referral
for treatment improves the
probability of clinical success. Image-guided fluoroscopy provides an accurate
way to treat the disease locally in its earliest stage.
Early treatment may help
avoid or delay development
of chronic and irreversible
joint changes and the associated pain and loss of function.
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* This research was presented at the
2006 Society of Interventional Radiology
annual conference and is accepted for
publication in Pediatric Radiology.
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Paget’
Paget’ss Sarcoma: A Retrospective Review
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The purpose of this project
was to contribute to a nationwide study aimed at developing new research and
treatment methods to help
individuals afflicted with
Paget’s sarcoma.
Paget’s sarcoma is a rare
form of bone cancer that
develops in individuals who
are in the advanced stages of
Paget’s disease—a disease
characterized by abnormal
and excessive remodeling of
bone. In response to the
excessive osteoclastic bone
resorption, osteoblasts arrive
and fill in the areas of resorption with new bone.
Due to the rapid activity
of osteoclasts, the osteoblasts
overreact and make excess
bone that is abnormally large
and chaotic. The resulting
bone is less dense and prone
to deformities and pathologic fractures. The disease
can affect one bone (monostotic) or multiple bones
(polyostotic). In the early
stages of the disease, the
affected bone becomes tender and appears enlarged
upon x-ray (see Figure 1).
A small percentage of
patients with Paget’s disease
develop Paget’s sarcoma.
This usually occurs in individuals who have been affected by polyostotic Paget’s
disease for many years. Patients with Paget’s sarcoma
present with severe, unremitting pain, a palpable mass
around the involved bone
and often with a pathologic
fracture. Paget’s sarcoma is a
malignant bone tumor that
carries an extremely poor
prognosis.1

One of the primary reasons for the high mortality
rate is that Paget’s sarcoma
mainly affects individuals
over 65 years old. In addition to the poor health of the
affected age group, the tumors are extremely aggressive and prone to pulmonary
metastases due to the increased vascularity of the
affected bones.
This retrospective study

Figure 1. Paget’s sarcoma of the
humerus and radius1

consisted of 16 patients afflicted with Paget’s sarcoma.
The average age of cancer
onset was 67.5 (range: 52–
91) years old. Surprisingly,
there were three patients
diagnosed with Paget’s sarcoma in their early 50s. In
the sample population, 75
percent of the patients were
male. The malignant tumor
affected only one bone in
nearly all of the patients.
However, in two individuals,
two different bones possessed the sarcomatous tumor. One of these patients
possessed the cancer in the
femur and pelvis, while the
other patient was affected in
the humerus and pelvis.
Overall, the most frequently
affected bone, in seven patients, was the humerus.
Other afflicted sites included
the pelvis (four patients),

femur (four patients), radius
(one patient) and thoracic
vertebral body (one patient).
Due to the rapid progression of the tumors, radical
surgery needed to be performed on most of the patients. Eleven amputations
and two wide surgical excisions were conducted, and
three patients received radiation therapy alone. Unfortunately, most patients died
from lung metastases and
only two patients survived
the disease. The average
time from diagnosis to death
was 1.75 years (range: three
months to seven years).
Despite significant advances in the treatment and
survival of most bone sarcomas, Paget’s sarcoma remains an extremely fatal
disease. The survival rate for
this cancer is less than 15
percent, despite the use of
aggressive surgery, radiation
and chemotherapy. Hopefully future research and new
treatment methods can be
developed to improve the
outcomes for patients with
this destructive malignancy.

REFERENCE:
1. Enneking W. Paget’s Disease.
Clinical Musculoskeletal Pathology. Gainesville: University of
Florida Press; 1998:10:13-19.
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fMRI Used to Define Language Organization in Epilepsy

Jay Zeck, MSII
Advisor: William Gaillard, MD
National Institutes of Health
Bethesda, MD

Medicine is stepping closer
to understanding how the
brain is used for language
and how ordinary language
organization may be reworked in patients with epilepsy. A very effective,
noninvasive tool used to
study the brain is a functional magnetic resonance
imaging (fMRI) scanner.
fMRI uses a conventional
magnetic scanner in a fashion that allows rapid images
to be taken of brain activity.
Each region of a subject’s
brain used to perform a task
has a blood flow response
identifiable by the scanner.

Figure 1. Sample
fMRI brain
activation maps
of epileptic
patients while
performing
auditory
description
tasks in the
scanner.

This study examined scanner
responses in a large sample
of epilepsy patients and normal, healthy volunteers (controls) under the clinical guidance of pediatric neurologist
William Gaillard, MD, of
the Children’s National
Medical Center and the National Institutes of Health.
Each participant in the
study was presented with a
language-related task while in
a 3 Tesla MRI scanner. Each
participant was given a series
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of simple sentences that were
true or not (e.g., “something
you sit on is a chair” or
“something you sit on is
spaghetti”). If the sentence
was true, the participant
pushed a button. Tracking
the performance helped ensure that the subject was
concentrating on the given
task while in the scanner.
Language centers traditionally reside in the left
hemisphere of the brain;
however, different patterns
persist more commonly in
epilepsy patient populations.1
Three study groups were
defined: epilepsy patients
with right or
bilateral language centers,
epilepsy patients with left
language centers and a
group of controls.
This study
concentrated
on the temporal lobes, noting any differences between
the epilepsy
patients and the controls on
brain activation maps (see
Figure 1 for examples). The
geometric distances between
the points of activation in
the control versus patient
groups were then calculated.
This study suggested that
there was reorganization
intra-hemispherically and/or
inter-hemispherically due to
epileptic interruption of language networks. The epilepsy
patients with left hemisphere
language dominance used a

wider region of their dominant temporal lobe to accomplish the same task as
the controls. In addition, the
region was significantly more
posterior and superior than
that of the controls. These
findings may indicate the
occurrence of dominant
hemisphere reorganization in
the wake of dominant hemisphere epilepsy. Furthermore, this study notes that
pathology can also shift language activation to the right
hemisphere, as shown by the
epilepsy patients. Language
centers of activation in these
individuals were found to
tightly cluster around a point
in the right hemisphere temporal lobe that is otherwise
active on the left side in controls.
These findings provide a
clearer picture of the disturbances that epilepsy can
cause. By showing differences in reorganization, researchers can better define
how the brain can cope with
epilepsy. Still, the exact
mechanism of how epilepsy
interrupts language remains
unknown. However, knowing precisely what brain regions epilepsy disturbs may
ultimately lead to understanding how it affects the
brain, which could impact
future treatments.

REFERENCE:
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et al. Distinct right frontal
lobe activation and language
processing following left hemisphere injury. Brain. 2005;
129(3):754-766.
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Hippocampal Activation May Not Predict Memor
Memoryy for
Auditor
Auditoryy Events

Shannon Gladman, MSII
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Children’s National Medical Center
Washington, DC

Fusion • 2007

Together with neurologist
William Gaillard, MD, and
his colleagues at Children’s
National Medical Center in
Washington, DC, studies
were conducted to assess
hippocampal activation,
memory performance and
cerebral language lateralization in children using functional magnetic resonance
imaging (fMRI) and neuropsychological tests.
This research was part of
a larger project undertaken
to determine differences in
the location of language
function in the brains of
children with epilepsy. This
information would facilitate
the surgical removal of brain
tissue in children whose
epileptic seizures seriously
disrupted their daily activities.
Most individuals have
receptive language functions
isolated primarily to the
temporal lobes of the left
hemisphere; however, patients with injury or impaired normal function of
brain tissue, as seen in
stroke or epilepsy, are likely
to have language functions
shifted to other areas of the
brain.1 Understanding this
shift is invaluable in planning neurosurgical intervention and expanding our
knowledge of brain organization and plasticity.
Epilepsy is a condition in
which normal signaling between neurons is disrupted,
resulting in paroxysmal periods of altered consciousness

and stereotyped motor activity. Prior to resecting a portion of brain tissue, a surgeon must ensure that areas
crucial to the patient’s normal function, such as lan-

Results suggest that
injury to the left
hippocampus may
not mediate language reorganization in the temporal neocortex.
guage, are not removed.
Neuropsychological tests
were administered on 42
children—21 epilepsy patients and 21 normal participants. Tests included the
Wide Range Assessment of
Memory and Learning
(WRAML) to evaluate each
child’s capacity for learning
and memory,2 and tests for
each child’s verbal intelligence. The children then
listened to a two-and-a-half
minute story while undergoing fMRI. Once removed
from the scanner, each child
was asked a series of questions about the story to assess his or her memory performance.
Using a magnetic field to
detect changes in blood flow
corresponding to changes in
neural activity, fMRI records
brain activation when a person performs a particular
task—in this case, listening
to a story. After determining

which side of the brain had
the greatest language activation, a computer masking
program was used to isolate
hippocampal activation. The
hippocampi, located in the
medial temporal lobes of the
brain, are involved in learning and memory.
This study postulated that
the degree of left hippocampal activation during a verbal
task would correlate with the
side of language dominance.
A relationship between hippocampal activation and
language dominance was not
found, suggesting that injury
to the left hippocampus may
not mediate language reorganization in the temporal neocortex, which was recently
proposed as a mechanism of
language reorganization. A
more precise understanding
of learning and memory and
their relation to language
function during development
provides the basis for more
successful outcomes with
neurosurgical intervention in
cases of epilepsy and other
disorders.
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Comparison Study of Patients with Stages IIIC and IV
Epithelial Ovarian, Fallopian TTube
ube and
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Primaryy Peritoneal Cancers
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Women who develop primary epithelial, fallopian
tube or peritoneal carcinoma
will most likely present with
advanced-stage disease.1 Optimal cytoreduction for advanced disease varies in literature from 15 to 85 percent; however, patients who
have undergone extensive
upper abdominal procedures
report optimal cytoreduction
rates greater than 50 percent.2,3
The optimal primary
cytoreduction rate at Memorial Sloan-Kettering Cancer
Center (MSKCC) has been
less than 50 percent. In
these cases, upper abdominal
resections were not performed and thus residual
disease often involved the
diaphragm, liver and/or
spleen.4,5
In the beginning of 2001,
MSKCC modified its surgical approach to patients with
advanced ovarian, fallopian
tube or primary peritoneal
carcinoma by integrating
extensive upper abdominal
procedures, such as diaphragm stripping and/or
resection, splenectomy, distal
pancreatectomy, partial liver
resection, resection of tumor
from the porta hepatis and
cholecystectomy. These
modified surgical procedures
were used at the discretion
of the primary surgeon to
obtain optimal residual disease status.6 This study com-

pared surgical events and
results in patients who underwent surgery between
January 1996 and December
1999 or between January
2001 and December 2004.
The latter group included
more extensive upper abdominal resections.

(Adapted from Drake RL, Vogl, W,
Mitchell A. Moore K, Dalley A. Gray’s
Anatomy for Students. Philadelphia:
Elsevier; 2005).

The MSKCC Gynecologic
Service Database was used to
compile information on all
patients with stages IIIC and
IV epithelial ovarian, fallopian tube and primary peritoneal carcinomas. These
patients had undergone primary cytoreductive surgery
at MSKCC between January
1996 and December 1999 or
between January 2001 and
December 2004. Patients
who had undergone surgical
procedures from January
2000 to December 2000
were excluded from the study
because those surgeries did
not routinely include the use

of extensive upper abdominal surgical procedures and
the surgical prototype of the
service had not yet changed.6
Furthermore, patients
were excluded from the
study if they had completed
neo-adjuvant chemotherapy
or primary cytoreductive
surgery at another institution, or if they had low malignant carcinomas, such as
mucinous or carcinosarcoma
histologic types. In addition,
stage IIIC patients who did
not present with bulky disease greater than two centimeters, but rather presented
with positive lymph nodes,
were further screened out.
The following information
was extracted from the patients’ medical records: age
at diagnosis, date of primary
surgery, primary site of disease, tumor grade, histology,
pre-operative serum CA-125
level, platelet size, location of
largest tumor mass, amount
of ascites, surgical procedures performed, size of
largest residual, site(s) of
residual tumor, estimated
blood loss, number of units
of blood transfused intraoperatively, intra-operative
complications, operative
time, length of hospitalization, primary chemotherapy,
result of chemotherapy, date
of second look, outcome of
second look, last follow-up
and current state.
Although the data has
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not yet been analyzed, the
hypothesis is that patients
who underwent surgery at
MSKCC between January
2001 and December 2004
show improved rates of optimal primary cytoreduction
and survival over patients
who had surgery between
January 1996 and January
1999 when extensive upper
abdominal resections were
not performed.
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The rising popularity of cutaneous laser surgery as an
accepted therapy for various
skin pathologies, coupled
with the diverse face of the
patient population, has led to
increasing demands for researchers to investigate laser
treatment on darker skin
tones.
United States population
statistics reveal dramatically
shifting demographics in the
past decade, with 85 million
colored individuals in the
U.S. in 2000.1
However, most of the
current literature is devoted
to examining laser procedures performed on individuals with fair skin tones
(skin phototypes I-II), and
protocols have largely been
defined on the basis of these
limited patient studies. This
research focuses on examining recent clinical research
of laser surgery on dark skin
tones to modify the standards for laser treatment of
vascular-specific, pigmentspecific, and ablative and
non-ablative skin resurfacing.

Due to its unusually wide
absorption spectrum ranging
from 250-1200 nanometer
(nm), melanin can be specifically targeted by all visiblelight and near-infrared (NIR)
dermatologic lasers currently
in use. In the darkly pig-

parameters, therefore, must
be carefully considered when
performing laser surgery on
patients with darker skin.2,3
Although difficult, effective laser therapy in patients
with darker skin can be
achieved since the absorpDermatologic
lasers have been
used for more
than four
decades to treat
a variety of
cutaneous
conditions, but,
until recently,
have been limited
to use in patients
with pale skin.

mented patient, nonspecific
energy absorption by relatively large quantities of
melanin in the basal layer of
the epidermis can increase
unintended thermal injury
and lead to a higher risk of
unfavorable side effects, including permanent
dyspigmentation, textural
changes, localized degeneration and scarring. Treatment

tion coefficient of melanin
decreases exponentially as
wavelengths increase.4-8 Laser
systems generating wavelengths that are less efficiently absorbed by endogenous melanin can often
provide a greater margin of
safety while still achieving
satisfactory results.9 Conservative power settings should
be initially employed to
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Dermatologic lasers have
minimize the extent of collatNd:YAG (neodymiumbeen used for more than
eral tissue damage. Clearly, a
doped:yttrium aluminium
four decades to treat a variprudent approach to treatgarnet; Nd:Y3Al5O12), 694
ety of cutaneous conditions,
ment is far preferable to
nm ruby, 755 nm alexandrite
but, until recently, have been
incurring the risk of irrepaand 1064 nm Nd:YAG larable tissue
destruction
resulting from
excessive thermal injury.
Vascularspecific laser
systems include a wide
array of Quality- or Qswitched,
pulsed and
quasi-continuous wave lasers generating green or
(Courtesy of Gray, H. Anatony of the Human Body. Philadelphia: Lea & Febiger; 1973).
yellow light
with wavelengths rangsers. The far-infrared waveing from 532-600 nm. Since
limited to use in patients
577 nm represents a major
lengths generated by the alexwith pale skin. This research
absorption peak of oxyhemoandrite and Nd:YAG laser
showed that recent developglobin, the 585 nm
systems are less efficiently
ments in laser technology
flashlamp-pumped pulsed
absorbed by epidermal melahave generated safe and efdye laser (PDL) has proven
nin, which limits the extent
fective means to treat pato be the most vascular speof unwanted thermal injury
tients with heavily pigmented
cific.
to nontargeted tissues of the
skin.
Pigment-specific laser
epidermis and upper papiltechnology generates green,
lary dermis, allowing for
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My first patient in Kenya
died. On the first morning
of my eight-week internship
at the Shikokho Medical
Clinic, I was wide eyed and
ready to learn, but I could
hear a boy’s labored breathing before I even entered the
clinic gate.
To treat what appeared to
be an asthma attack, the
nurses and I pumped as
many bronchodilators and as
much epinephrine as we
could into his small body.
Each injection did not significantly help his breathing
as we had hoped and I felt
unsure of what to do next.
Without access to an emergency phone number, ambulance or viable transportation
out of the village to a bigger
or better equipped health
facility, the boy would die.
The nurses knew that. Since
there was no access to another facility, the boy eventually stopped breathing.
It was difficult not to
think about the possibilities
that might have existed for
the boy in the U.S. with
access to proper emergency
care. But this was Shikokho,
Kenya, a small village of
about 1,500 where medical
and social problems are
vastly different from those in
America, and, at times,
seem grossly magnified.
Shikokho is part of

Ikolomani Division, the
poorest division in the
Kakamega District in the
Western Province of Kenya.
Kakamega is the third poor-

One morning I visited St.
Elizabeth’s Hospital of
Mukumu, the nearest facility
with emergency services and
a government-approved HIV

est district of more than 70
in the country and is inhabited mainly by subsistence
farmers of the Luhya tribe.
The estimated HIV rate for
the Western Province is
more than 25 percent.1
The developmental health
issues the Shikokho community faces center on access.
Shikokho is 10 kilometers
(6.2 miles) away from the
nearest facility that can perform emergency services,
such as surgeries, or provide
free HIV testing and antiretroviral treatment. Add to
this that roads can only be
traversed by foot and become virtually impassable
after a heavy rain. The distance and conditions prevent
a large sector of the population from receiving critical
services.

testing and treatment facility.
I went to inquire about the
possibility of partnering with
the hospital for referrals of
emergency patients, including the use of the ambulance
to Shikokho. Perhaps because I was a mzungu
(Swahili for white person),
the administrators agreed
and immediately gave me
four phone numbers for the
nurses at Shikokho to call to
transport a patient, including
mobile phone numbers for
the hospital administrator,
head doctor and matron
(nurse in charge). With this
assistance from St.
Elizabeth’s Hospital, an
emergency or serious health
problem would not result in
a death sentence for someone living in Shikokho.
During the third week of
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my internship, a collaborative effort by the Kenyan
Ministry of Health, the
World Health Organization
(WHO) and the United Nations International Children’s
Education Fund (UNICEF)
allowed for a five-day distribution of measles vaccinations, Vitamin A and mosquito nets at all health facilities in Kenya, including the
Shikokho Medical Clinic.
Previously, it had been an
enormous struggle to reach
young women isolated at
their shambas (farms).
This campaign gave the
clinic staff, including myself,
a unique opportunity to give
talks about malaria and the
proper use of mosquito nets
to more than 500 young
mothers in the community.
In the Western Province,
HIV prevalence is 4.8 percent, but 5.8 percent among
women and 8.9 percent
among pregnant women.1
Agnes, a respected HIV-

positive midwife, gave several health talks to the
women on the importance of
knowing one’s HIV status
and getting anti-retroviral
treatment if HIV positive.
The women responded enthusiastically and showed
appreciation to the clinic
staff for teaching them how
to prevent disease in themselves and their families.
During the last week of
my internship, the first HIV
voluntary counseling and
testing (VCT) day took place
at the Shikokho Medical
Clinic. After weeks of brainstorming how to legally perform HIV testing at the
clinic, an arrangement was
made with St. Elizabeth’s
Hospital to perform a
monthly outreach at the
clinic. Using bars of soap as
incentive, the first VCT
event enabled 53 villagers,
including 12 pregnant
women, to be tested, counseled and referred for treat-

ment when necessary.
After being introduced to
some of the critical health
problems facing the
Shikokho community during
my first week, I could not
have imagined some of the
creative solutions that
evolved in the following eight
weeks. I was told by many
people to move slowly and
cautiously and not expect to
see any results in this short
amount of time. This was
termed “realism.” But I
found it difficult to proceed
pole, pole (slowly by slowly)
when the urgency of these
life-and-death situations took
hold of me. Though the
health problems facing
Shikokho are by no means
solved, I was able to be a
part of many beginning
stages of solutions.
Having this unique and
amazing experience as a
medical student opened my
eyes to international health
issues and how I can play a

role. I have felt the drive to
work in the realm of international public health for many
years. This internship affirmed and solidified my
desire. I discovered strengths
and abilities I did not know
I possessed. I found that I
was driven by the needs of
the community and would
do almost anything in my
power to address these
needs. Instead of becoming
disillusioned by the many
obstacles, I became empowered to do whatever I could
to help. I feel that my summer experience is best epitomized by former President
Jimmy Carter’s words,
“Once we understand, we
can care; and once we care,
we can change.”
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Although Costa Rica’s capital
and largest city serves as the
arrival and departure point
for many tourists, San José
is often overlooked by the
many sightseers who are
eager for more “exotic” attractions.
Containing approximately
half of the entire country’s
population, the greater metropolitan area of San José
consists of not only native
Costa Ricans but also a large
percentage (estimated at 40

percent) of Nicaraguan refugees.1,2 They mostly live in
segregated areas around the
city where they struggle
against discrimination for a
better life. As a result of
their illegal status, many
Nicaraguans are denied
medical care.3 This article
discusses my personal experiences working with Nicaraguans in Costa Rica through
the Foundation for International Medical Relief of
Children (FIMRC), an orga-

nization started by Vikram
Bakhru, MD, a GW medical
school alumnus who graduated in 2001. He is now in
his Surgery residency in
Philadelphia, but still manages FIMRC. This article
discusses how such a population can help volunteers understand and appreciate the
power of caring and compassion in medicine.
I met FIMRC’s Medical
Director, Cristian Elizondo,
MD, the day after I arrived
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in Costa Rica in February
2006. I expected to meet a
serious middle-aged physician, but I instead came
across a man not much older
than myself, wearing jeans
and a trendy T-shirt and joking with a friend on his cell
phone. Seeing this man relieved me and his easygoing,
casual attitude alleviated my
previously grim and serious
outlook toward this volunteer project. Dr. Elizondo’s
demeanor and casual way of
dressing would have probably made people in the U.S.
skeptical or less confident in
him as a physician. But in
Costa Rica, this was very
appropriate. Dr. Elizondo
understood that his patients
felt most comfortable with
him if they could look at
him as a friend.
A new clinic was being
built by FIMRC, but it was
still under construction.
Over the next several days, I
visited some of the “ghettos,” or what the local Costa
Ricans
called the
Nicaraguan
communities
around
San José,
and we
set up an
on-site
clinic in
one of the
ghettos.
Utilizing my basic abilities in Spanish, I helped with
patient charts, medication
distribution and health education lessons as Dr.
Elizondo examined patients.
Without sophisticated equipment or tests, Dr. Elizondo
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A View of “Los
Pinos” (The Pines),
a community outside
of San José where
many Nicaraguan
refugees live without
medical treatment
and suffer from
poverty,
discrimination and
drug and crime
problems.
(Courtesy of Sarah
Eberhart)

was limited to practicing
good medicine with his
words and his hands. I did
not see any life-saving procedures or any serious cases
the week I was there, but the
patients taught me valuable
lessons and were a great testament to the foundation of
compassion and caring in
medicine. The genuine gratitude expressed by these
people, even as I misspelled
their
names
and made
them
repeat
words
again and
again,
was overwhelming. Despite several sick
and upset
children hanging on her, one
woman kept a very patient
smile on her face while I
tried my best to take her
children’s histories. She even
wanted to take the time to
ask me about my life and my
work in Costa Rica. Most

patients were just happy
someone wanted to help and
care for them.
I took a second trip to
Costa Rica for a week in July
2006 when the new clinic
opened. An average of 20
patients visit the clinic daily
and FIMRC has expanded
its services to include a child
psychologist and a support
group for mothers suffering
from psychological problems
and abuse that often accompany poverty. Dr. Elizondo
and everyone else at FIMRC
have worked hard to give the
Nicaraguan population a
sense of belonging, worth
and the relief that comes
with knowing someone is
there to help in times of
need. What I found to be
most memorable was that,
without fancy diagnostic
equipment or technology, we
were able to help and bring
hope to a population that
goes largely ignored. With so
much emphasis in the U.S.
on state-of-the-art medicines
and technologies, it was extremely valuable to see how a
doctor’s listening ear and
compassion could do so

much. With this lesson in
mind, I hope to be able to
always focus on the relationships I establish with my
patients. My experience with
FIMRC and the people in
the Nicaraguan ghettos was
eye-opening, humbling and a
great way to remind me of
my future goals as a medical
student and beyond.
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Most mammals make vitamin C in the liver with enzymes that convert glucose
into vitamin C. Humans,
however, lost the ability to
do this. Therefore, humans
must get their vitamin C
from an outside source,
namely from their diet.
Vitamin C is necessary
for several important functions in the body and for its
role as an antioxidant.1 On
the membranes of red blood
cells, vitamin E has the ability to reduce peroxides and
be regenerated by vitamin C.
Vitamin C is also known as
a water soluble, chain breaking donor antioxidant. Vitamin C has the ability to reduce oxidative stress by either slowing or preventing
the oxidative progression
before it even starts. It does
this by directly interacting
with the chain-carrying radicals. It donates either a hydrogen atom or an electron
to the oxidant and is therefore able to prevent the
spread of cycle chain reactions. As a powerful antioxidant, vitamin C has been
shown to prevent atherosclerosis, cancer and various
cerebral diseases.
Vitamin C, also known as
ascorbate, enters cells

through the Sodium Dependent Vitamin C Transporter
2 (SVCT2). The oxidized
form, known as dehydroascorbic acid (DHA) and
obtained from the loss of
two electrons, enters cells
through the GLUT transporter. Once DHA gets inside cells, it is immediately
reduced to ascorbate via
glutathione (GSH) or
through thioredoxin reductase. Ascorbate’s high concentration in neurons in the
brain shows that the brain
relies on vitamin C for its
antioxidant properties. Thus,
it is important to study how
cells take up and recycle
vitamin C.
HT-22 cells, a neuronal
cell line derived from mouse
hippocampus, were chosen
for this study because they
contain many SVCT2 and
GLUT transporters. Results
from a Western Blot showed
that the SVCT2 transporter
was present at 75 kilodaltons
(kD). Results from highperformance liquid chromatography (HPLC) showed
that as increasing amounts of
ascorbate were added to the
cells, there was a progressive
uptake of ascorbate up to 16
millimolar (mM) intracellular
concentration. When adding

increasing amounts of DHA
to the cells, there was a linear uptake of DHA and reduction to ascorbate, which
only went up to 1 mM ascorbate.
These results illustrated
that, since DHA is using the
GLUT transporter, glucose
could be competing with
DHA for entry into the cell.
When glucose was removed
and DHA was added to the
cells, a rapid linear increase
in the intracellular levels of
ascorbate was observed back
up to 16 mM, showing that
glucose was competing with
DHA for entry into the cell.
When increasing concentrations of glucose were added
to the cell media, there was a
progressive decrease in
DHA uptake, and therefore
a decrease in recycling DHA
to ascorbate.
Clearly, glucose acts as a
competitive inhibitor. DHA
was shown to be dependent
on GSH for reduction to
ascorbate because when
agents that inhibited GSH
synthetase were added, there
was a 70-99 percent decrease
in intracellular ascorbate,
depending on the agent used.
When people without
diabetes are exposed to oxidant stress, such as coronary
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artery disease, some ascorbate gets oxidized to DHA
and goes into the area of
ischemia. Once DHA gets
into the cells, it is recycled
to ascorbate, a form that can
act as an antioxidant. DHA
uses GLUT transporters for
entry into cells. However,
people with uncontrolled
diabetes lose the ability to
uptake DHA due to the
competing nature of glucose.
Therefore, less DHA is recycled to ascorbate and less
ascorbate indicates a decreased ability to deal with
oxidant stress. A diabetes

patient who develops ischemia will have a problem
getting DHA into the cells
and recycling it back to
ascorbate.2 This is especially
important when considering
that the blood-brain barrier
lacks SVCT2 transporters
but contains DHA transporters. Further studies are being conducted to see how
HT-22 cells deal with oxidant stress, such as
glutamate, and the effect the
stress has on direct reduction with GSH and ascorbate
uptake.

The purpose of this
project was to better understand the role of vitamin C
in the HT-22 cell line. If one
understands how these cells
use vitamin C, how vitamin
C gets recycled and what
effect these cells have on
oxidative stress, one can
then make connections with
the importance of certain
levels of dietary intake that
are required for vitamin C
to be beneficial to patients.
Researchers can then relate
these findings to diseased
states so that patients can
better understand the impor-

tance of vitamin C in the
protection from oxidative
stress.
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Type 2 diabetes mellitus is
one of the most significant
health threats in the world.
The World Health Organization estimates that approximately 170 million people
are afflicted with this disease. Since this number is
expected to double within
the next two decades,1 it is
important to gain a better
understanding of the disease
and find better ways to control this growing problem.
The type 2 diabetes mellitus whole genome association study gathers genetic
variation2 by genotyping
Single Nucleotide Polymorphisms (SNPs), which are
variations of a single nucleotide that occur in at least
one percent of the population, from patients with
adult onset type 2 diabetes
mellitus. This private-public
partnership, a collaboration

between the Broad Institute,
Novartis Institutes for Biomedical Research and Lund
University in Sweden, promotes open sharing of information and hopes to show
that the benefits of this
openness will outweigh the
benefits of secrecy. After the
quality of the data is assured,
the primary analysis results
will be posted online for
public access.
For this research, case
and control subjects from
Sweden and Finland were
matched using two methods:
traditional case control and
discordant sibship. For the
traditional case control, one
or two subjects with adult
onset type 2 diabetes mellitus were matched with one
or two controls on the basis
of sex, body mass index
(BMI), age and geographical
region. The ages of the con-

trols were within 20 years of
the matching cases. The
cases and controls were seen
at the same clinical site and
were from the same geographical location. Cases and
controls were determined by
the ADA3 definition for type
2 diabetes and normal glucose tolerance (NGT). For
discordant sibship, each
sibship group consisted of
three or four subjects, including one or two affected
siblings and one or two unaffected siblings. This group
was chosen using the same
selection criteria as the traditional case control.
The study’s 2,881 subjects were genotyped using
the Affymetrix GeneChip
500k, which contains
500,000 SNPs.
While the Affymetrix
GeneChip 500k provides
data in terms of SNPs, this
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analysis requires the dataset
to be organized by genes.
One representation was created by matching a compiled
list of 32,634 relevant genes
to the SNPs within and
around the gene. This representation of genes was tested
under the stress of multiple
statistical methods to determine the statistical method
that most accurately embodied the data.4,5 PLINK, a
whole genome association
analysis software toolset, was
used to analyze this data.
Three gene-based association statistics were compared: 1) Max: a statistical
method using the top-performing chi square values for
each gene. 2) Sum: a statistical method using the sum
and normalization of up to
five chi square values for
each gene. 3) Hotelling’s T-

square: a multilocus, genotype-based test. The relationships between the 10 best
performing genes of each
statistical method were examined. A subset of nine
genes, mentioned in literature and thought to be related to diabetes, were chosen as a dataset of more
manageable size.
The release of these results is pending the completion of the project and the
public release of the genetic
and clinical information. In
the future, additional statistical methods will be used to
consider alternative representations of genes, including a model capturing epistasis (the interaction between
multiple genes) and sets of
related genes (such as the
genes in a particular metabolic pathway).6, 7 Multiple

gene representations and
statistical tests will hopefully
create a clearer picture of
the genomic influence on
type 2 diabetes and eventually lead to a better understanding of this disease and
more effective treatment
options.
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A stimulating two-hour lecture on human brain development during my first year
of medical school motivated
me to seek a summer research position in brain plasticity and function. A Gill
Fellowship allowed me to
conduct research in the laboratory of my Neurobiology
professor, Kenna Peusner,
PhD.
My project targeted the
changes in vestibular neurons of the brainstem during
recovery of function after a
peripheral vestibular injury.
The vestibular system is primarily responsible for main-

taining balance. Balance is
maintained by signaling in
three neuron reflex pathways
composed of vestibular ganglion cells in the periphery,
vestibular nuclei neurons in
the brain, and motor neurons. After losing the vestibular periphery on one side,
people exhibit symptoms of
nausea, vomiting, dizziness,
nystagmus, and the inability
to walk or eat. Without intervention, most of these
symptoms disappear naturally over the period of a
week, a process known as
vestibular compensation.
The present understanding is

that vestibular compensation
is due to brain plasticity,
involving a temporary loss of
neuronal excitability in vestibular nuclei neurons and
their recovery. The process
occurs not only in humans,
but also in other vertebrates,
including birds. I chose the
hatchling chicken as my experimental model because
the chicken is bipedal like
humans, has particularly
distinctive vestibular nuclei
and young chickens show a
higher degree of brain plasticity than adult chickens.1
The working hypothesis
of Dr. Peusner’s laboratory is
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that certain developmental
events involved in establishing neuronal excitability are
re-expressed during recovery
of function after injury. Furthermore, the laboratory is
focused on investigating specific potassium channels
during vestibular compensation. In particular, I studied
a potassium channel that can
be identified because of its
sensitivity to the snake

compensation.
I studied the principal
cells of the chicken tangential vestibular nucleus because these vestibular
nucleus neurons participate
in the vestibular reflex pathways (Figure 1).1 My project
involved learning immunocytochemistry, behavioral testing of operated hatchlings,
and confocal imaging and
analysis of these neurons. In

Figure 1. An
immunocytochemical image of
the principal cell body located
in the vestibular system’s
tangential nucleus. The
brighter regions surrounding
the soma indicate a greater
concentration of the Kv1.2
potassium channel protein
subunit.

venom dendrotoxin (DTX).
Surgery to remove the
vestibular periphery was
performed on four- to fiveday-old hatchling chickens,
which were sacrificed three
days afterward. Five-day-old
hatchlings were selected for
study because the neurons
achieve their mature excitability at this age.2 During
embryonic development,
these neurons exhibit high
levels of this potassium channel, which is lost after reaching maturity in five-day-old
chickens.3 I performed immunocytochemistry on fiveday-old normal chickens and
those with surgically removed vestibular periphery
to determine whether the
level of expression of the
protein Kv1.2, an essential
component of the DTXsensitive potassium channel,
changed during vestibular
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performing my tasks, I was
fortunate to have the opportunity to work alongside Dr.
Peusner as well as two research scientists, Anastas
Popratiloff, MD, PhD, and
Mei Shao, MD, PhD.
I began my summer fellowship by watching an experienced investigator perform
several vestibular ganglionectomy microsurgeries. While
performing the procedure
myself, I learned how delicate and demanding microsurgery on the inner ear can
be. However,
immunolabeling the sections
proved to be the biggest
challenge. It was critical to
determine the appropriate
timing to avoid over- or under-labeling the tissue sections with a particular antibody. Two secondary antibodies were used to visualize
the neuron cell bodies and

their synaptic terminals with
Kv1.2. I learned the importance of using fluorescent
dyes with excitation and
emission curves that do not
overlap to prevent false positive labeling.
I mounted the prepared
brain sections on glass slides
for confocal imaging. This
specialized microscope took
a fair amount of practice,
but after a few days I gained
proficiency. Using confocal
microscopy and lasers of
varying frequencies, I imaged at 60x magnification
the Kv1.2 protein expressed
in the principal cells and
their synaptic terminals.
I captured confocal image
stacks containing 50 images
for each of 76 principal cells
and thousands of synaptic
terminals. Using Adobe
Photoshop 7.0, I outlined
the immunolabeled components and analyzed the images for pixel brightness to
quantify the amount of
Kv1.2 protein expressed in
the synaptic terminals and in
the cytoplasm of the principal cells. Mean distribution
curves and standard deviation of the data are in
progress. I am continuing to
work in Dr. Peusner’s lab
during the school year to
finish the project.
The work I performed in
Dr. Peusner’s lab taught me
many lessons, both practical
and philosophical. I became
proficient at using the confocal microscope and I now
have a strong understanding
of digital image analysis. As
Dr. Popratiloff explained to
me, “Image analysis is a
highly evolving and useful
system in this new age of
digital computing.” I ac-

quired specific knowledge
and skills in behavioral testing of experimental animals,
microsurgery and image
analysis that have carried
over into my classroom studies.
The scientific implications of this work will provide insight into the cellular
and molecular mechanisms
controlling excitability in
vestibular nucleus neurons.
As these mechanisms are
better understood, molecular
targets will be identified and
more effective therapies may
be devised to treat central
vestibular disorders in humans resulting from disease,
injury or aging. From this, a
more concrete understanding
of brain plasticity and function may be achieved. As a
Gill Fellow, I witnessed firsthand how ideas and hypotheses about complex systems
of body function may be
explored in the laboratory,
and how the findings may be
translated to a better understanding of human health.
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Chemokines are a family of
low-molecular-weight proteins that appear to be involved in the costimulation
of T-cells. For this reason, in
addition to their well-established role in chemotaxis,
chemokines are being investigated for their use in cancer immunotherapies.
Cancer immunotherapies
aim to harness the potential
of the body’s immune system
to combat malignant tumors.
When positive therapeutic
responses are achieved, they
are generally attributed to
the induction of cell-mediated immune responses.1
This has proven challenging,
however, tumor cells appear
inherently effective at evading immune surveillance.
The poor immunogenicity of
these transformed, altered
self cells can be largely attributed to the suppressive nature of the local tumor microenvironment, owing, in
part, to the decreased expression of costimulatory
molecules.2
Costimulatory signals are
critical in the activation of
naïve T-cells. Once the T-cell
receptor (TCR)/CD3 complex has engaged its cognate
peptide-MHC presented by
an antigen-presenting cell
(APC), naïve T-cells must
receive a second signal to
drive clonal expansion and
differentiation into armed
effector cells. In the absence
of positive costimulation, Tcells that have encountered
antigen become anergic,

rendering them nonresponsive. Thus, a costimulatory
molecule must be capable of
sending and/or receiving
information that initiates an
intracellular signaling pathway that intersects with antigen-specific signals synergistically to allow for lymphocyte activation.3
Most costimulatory molecules belong to the B7/
CD28 and TNF/TNFR
families, while others belong
to the CD2-subset and
integrin/cell-adhesion molecule group.3 Their use in
cancer vaccines, often in
combination with a known
tumor-associated antigen,
offers a potentially efficacious means to initiate and
maintain cell-mediated antitumor immune responses.
Rationally expressing certain
costimulatory molecules in
the tumor microenvironment, based upon their spatial and temporal significance to the initiation and
maintenance of the immune
response, immunotherapists
can help shift the balance
from immunotolerance, tumor growth and survival to
T-cell activation and tumor
regression.2
An exciting finding is that
chemokines are emerging as
costimulatory molecules.4 Of
particular interest is CCL21,
a chemokine that is constitutively expressed by secondary
lymphoid tissue and attracts
CCR7-expressing cells,
which largely include mature
antigen-experienced den-

dritic cells (DCs) and naïve
T-cells. The effective communication between these
two cell types is crucial to
initiate cell-mediated immune responses. For these
reasons, CCL21 is being
investigated for its role in
the coordinated migration of
these cell types, as well as its
ability to costimulate the
proliferation and differentiation of naïve T-cells into
armed effectors.
Murine CCL21 has already been shown to
costimulate naïve T-cell expansion and Th1 polarization
of non-regulatory CD4+ Tcells, and to a lesser extent,
the increased proliferation of
CD8+ T-cells.5 However, it
cannot be assumed that human CCL21 is capable of
the same, as significant discrepancies exist between the
innate and adaptive immune
systems of mice and humans.6
Researchers have previously demonstrated the
costimulatory expansion of
peripheral blood mononuclear cells (PBMCs) with
the structurally related, but
functionally dissimilar
chemokines CCL3, CCL4
and CCL5.7 These three
chemokines are members of
the inflammatory chemokine
subfamily, whereas CCL21
belongs to that of the homeostatic or lymphoid
chemokines. While both
subfamilies have chemotactic
properties, their differential
expression profiles may carry
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implications toward their
intrinsic ability to function
in costimulation.8
As our interests are inclined toward translational
research, it is of great importance to provide supportive evidence that the observations made in murine
models may also hold true in
the clinical setting. We have
begun to conduct numerous
in vitro cell proliferation
assays to test the ability of
human CCL21 to
costimulate cell division in
PBMCs, as well as sorted
CD4+ and CD8+ T-cells, all
of which have been harvested from healthy human
donors. Positive findings
here will help provide a supportive rationale for integrating human CCL21 into cancer vaccines as an adjuvant

to therapy. As the immune
system is elegantly regulated
by a cascade of complex
interactions that resemble a
rheostat, rather than an onoff switch,9
immunotherapists must tip
the balance of positive and
negative costimulatory signals in a way that achieves
appropriate levels of T-cell
activation that can lead to
the eradication of tumors,
devoid of significant, undesired autoimmunity.10 Targeting specific costimulatory
pathways, particularly those
of the chemokine family, can
allow for the fine tuning of
various spatial and temporal
aspects of cell-mediated immune responses, helping to
increase the safety and efficacy of cancer vaccines.
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Cancer is a leading cause of
death in the United States
each year. With current standard therapy options, the
long-term survival rate over a
five-year period hovers
around 65 percent.1
With a growing understanding of the immune system, researchers have determined that the immune system fights off foreign pathogens and is utilized against
malignancy.2 These discoveries have opened the door for
a new cancer treatment
method—cancer immunotherapy.
Cancer immunotherapy

uses the body’s own natural
immune defenses to fight
cancer. It has two main benefits over current treatment
options. With the use of
antibodies, therapeutic treatment can be directly targeted
to specific tumor sites. This
allows for more concentrated
drug delivery and effective
results. Targeted delivery also
localizes toxicity while decreasing harmful systemic
side effects.
The Tumor Necrosis
Treatment (TNT) antibody
was engineered to bind to
intracellular antigens in degenerating cells. The anti-

body binds to necrotic regions of solid tumors all
over the body.3-5 Specifically,
the liver expression
chemokine (LEC)/chTNT-3
fusion protein, which binds
to the necrotic region and
chemoattracts T-cells, Bcells, and NK-cells to the
tumor site, has proven to
greatly reduce tumor load
and metastatic spread of the
tumor.6 However, the intracellular consequences of
LEC binding to and activating immune cells are unknown.
In this study, second messenger and receptor tyrosine
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LEC stimulation pathway.
The JAK-STAT signaling
pathway takes part in the
regulation of cellular responses to cytokines and
growth factors. The pathway
transduces the signal carried
by extracellular polypeptides
to the cell nucleus, where
activated STAT proteins
modify gene expression. The
pathway plays a central role
in principal cell fate decisions, regulating the processes of cell proliferation,
differentiation and
apoptosis. It is particularly
important in hematopoiesis.
Because of its involvement in

LEC

blood cell gene expression,
we chose to look into its
possible role in immune cell
activation. There were no
significant changes in
STAT3, a protein-coding
gene involved in the JAKSTAT pathway. There were
also no significant changes in
the catalytic subunit of protein kinase A (PKAc) involved in another G protein
coupled receptor pathway.
Protein kinase G (PKG)
is another protein kinase
downstream to a G protein
coupled receptor pathway.
One hour after LEC stimulation, THP-1-0 cells showed a
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Figure 2. Changes in PKG
expression in THP-1-0
monocytic leukemia cells after
5 minutes, 1 hour and 18
hours of LEC stimulation for
PKG. Results were normalized
to actin to control for protein
loading discrepancies. Ox40
serves as a second control
sample.

Figure 1. Changes in
phospho PKC delta
expression in THP-1-0
monocytic leukemia
cells after 5 minutes,
1 hour and 18 hours
of LEC stimulation
for phospho PKC
delta. Results were
normalized to actin
to control for protein
loading
discrepancies. Ox40
serves as a second
control sample.

Normalized Density

kinase pathway protein expression levels were analyzed
by Western blot in THP-1-0
cells, a monocytic leukemia
cell line. Protein levels were
measured before and after
LEC stimulation to determine the intracellular signaling molecules responsible for
immune cell activation.
Protein kinase C (PKC)
delta is a specific protein
kinase in the Phospholipase
C pathway, a very common
signal transduction pathway.
In previous LEC studies,
blockers of this pathway
have led to decreased
chemotactic activity in response to LEC by immune
cells.7 A Western blot was
performed to determine
phosphorylated (phospho)
and unphosphorylated PKC
delta protein levels in monocytic leukemia cell lines exposed to LEC. A significant
change in PKC delta protein
levels was not seen, but there
was a significant increase in
phospho PKC delta protein
concentration 18 hours after
LEC stimulation (Figure 1).
These results indicate that
PKC delta plays a role in the

2

OX40

significant decrease in PKG
protein levels compared to
unstimulated cells (Figure 2).
These results elucidate the
intracellular signaling pathways involved in LEC-mediated cellular activation. In
the future, these findings can
be used to understand the
mechanism of LEC-induced
immune cell recruitment to
fight cancer.
Another research project
aims to selectively knock out
T-regulatory cells from the
rest of the T-cell population
since T-regulatory cells limit
the immune response against
malignancy.8,9 This Western
blot technique could
be used to investigate intracellular
signaling pathways
targeted to specifically destroy T-regulatory cells while
keeping other T-cell
5 min
populations intact.
1 hour
18 hours
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The physiological stress response in animals, including
humans, is an adaptive
mechanism to fight or flee
from a threat. Observing this
response to stress in the
laboratory allows one to understand
the sen(Courtesy of
sory inforMarieb E.
mation
Human
and
Anatomy
and
mechaPhysiology.
nisms asCalifornia:
sociated
Benjamin/
with
Cummings;
stress.
1995.)
Longterm stress
disturbs homeostasis and
leads to a host of physiological and mental disorders and
reduces the ability of the
organism to cope with its
environment. One of the
major stress-activated neurotransmitters is neuropeptide Y (NPY), which appears
to inhibit the stress response
and improve memory in the

brain.1 The three goals of
this project were to elucidate
the neural mechanisms that
enhance learning and
memory under stress, identify the physiological limits
at which these mechanisms

fail and determine the role of
NPY and its receptors in
these processes.
Auditory fear conditioning provides a quantifiable
paradigm for dissecting out
the neural circuits and synaptic mechanisms that regulate memory and learning
and can be modified by
stress. The resultant physi-

ological stress response can
be quantified by measuring
associated changes in activation of the following systems:
sympathetic nervous (catecholamines), adrenal cortical (corticosterone) and cardiovascular (heart rate and
blood pressure). To determine if these changes are
related to activation of the
NPY system in the brain,
expression of the peptide
and its receptors (Y1-Y5)
were studied in different
parts of the brain, including
the cortex, amygdala, hippocampus and hypothalamus. It was predicted that
NPY would play a significant
part in modulating stress in
neurons.
In order to understand
NPY’s role in modulating
stress, mice were conditioned by pairing an unconditioned stimulus/stressor
(mild electric foot shock)
with a battery of complex
auditory stimuli (harmonic
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stacks of frequency modulated sweeps). This established a learning curve for
categorical perception of the
conditioned stimulus. Next,
NPY or specific NPY receptor agonists were pressure
injected into the lateral ventricles prior to conditioning
to see direct behavioral
changes to a stressor with
increased NPY.
Although NPY’s role in
the physiological stress response has not yet been established, there is strong
evidence suggesting a direct
mechanism in regulating the
cardiovascular system.
Intracerebro-ventricular injection of NPY has been
shown to lower an increase
in heart rate associated with
auditory fear conditioning.2
It was also predicted that

this effect would reduce the
neuro-endocrine stress response, thereby extending
the ability of the animal to
recognize fine distinctions
between categories of auditory stimuli. Further insight
into NPY’s role will be gathered by monitoring levels of
stress by measuring plasma
corticosterone levels and
heart rate prior to testing
and before and after fear
conditioning and changes in
NPY receptors in the relevant brain areas.
Ongoing research will test
for any augmentation in the
stimulus-evoked local field
potentials (LFPs) in response
to the conditioned stimuli
within the amygdala and
hippocampus to localize the
sites of conditioned learning.
Mapping experiments will

determine stability (memory)
of the representation of
novel frequency modulation
stimuli with repeated conditioning. The effects of iontophoretic administration of
NPY or receptor agonists at
the recording site on the
spontaneous and stimulusevoked responses will be
studied as well as LFP responses at sites where augmentation is observed. These
results will delineate the neural substrates and synaptic
mechanisms involved in conditioned learning and the
role of stress in either augmenting or reducing this
effect. This knowledge will
shed light on how to prevent
the detrimental effects of
stress by either pharmacological or behavioral interventions during a stressful

experience rather than treating the physiological damage
from stress afterward at a
much greater cost.
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Erythropoietin (EPO) is a
hormone that regulates red
blood cell production and is
a powerful drug used to
manage anemic patients.
However, recent evidence
suggests that EPO’s use in
treating anemic cancer patients may be more harmful
than helpful.
EPO, also known by its
trade names Procrit and
Epogen, is manufactured by
pharmaceutical giants
Johnson & Johnson (J&J)
and Amgen. It is one of the
10 most prescribed drugs in
the United States, with
nearly six billion dollars of
combined sales in the past

year. Clinical oncologists had
high hopes of using EPO to
treat cancer patients suffer-

Administration of
pharmaceutical
erythropoietin promoted cancer cell
proliferation and
invasion.
ing from anemia, a common
side effect resulting from the
toxicity of radiation and
chemotherapy on the vascular system.

Two clinical trials designed by J&J and HoffmanLa Roche aimed to test the
safety and efficacy of EPO in
cancer patients. These trials
were prematurely terminated
when researchers discovered
high mortality rates and poor
disease-free survival in the
patient treatment groups that
were receiving EPO.
Until now, few researchers
understood the mechanism
behind such findings. The
laboratory of Ajay Verma,
MD, PhD, at the Uniformed
Services University of the
Health Sciences, has focused
its efforts on elucidating the
mechanisms behind EPO’s
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Figure 1. EPOR
expression on red
blood cell
precursors and
tumor cells.
(Courtesy of
Brower V.
Erythropoietin may
impair, not
improve, cancer
survival. Nature
Medicine. 2003;
9(12): 1439.)

role in cancer. Recent studies by Dr. Verma that will be
published in the Journal of
Neurosurgery1 provide insight
on the underlying mechanisms behind these clinical
observations. By studying the
roles of EPO and its receptor (EPOR) in brain cancer
progression and invasion,
this research may have determined how EPO mediates
these deleterious consequences.
The hypothesis was built
on several lines of research
that demonstrated that EPO
was a pleiotropic hormone
with a broad spectrum of
functions outside of the
hematopoetic system. Several groups have demonstrated that the EPOR is
found on tissues in addition
to red blood cell precursors,
including the brain, uterus
and breast (Figure 1). Surprisingly, it is highly expressed on the surface of
cancer cells derived from
these tissues.1-3
Using several cancer cell
lines derived from tissues
utilizing EPO signaling, this
research showed that the
EPOR was highly
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upregulated in these cells
compared to normal tissue.
In fact, administration of
pharmaceutical EPO promoted cancer cell proliferation and invasion. It was
postulated that ectopic EPO
and EPOR expression in
tumors is used as an

autocrine/paracrine mechanism for tumor proliferation
and metastasis to escape
several tumor stressors, such
as local tumor hypoxia, that
develops from an imbalance
of tumor vascular supply to
tumor volume ratio.
To empirically approach
this hypothesis, a dominant
negative EPOR that was
missing the cytoplasmic domain for cell signaling was
developed. Inhibition of
EPO signaling in cancer cells
reduced proliferation, invasion and in vivo tumor
growth in mice. Tumor volumes of brain cancer cells
with truncated-EPOR transplanted in nude mice were
almost three to four times
smaller than control cells
(Figure 2).

This work provides insight into how EPO promotes cancer malignancy.
Human cancers express EPO
and functional EPORs. High
expression of these proteins
in several human cancers
makes EPO signaling an
attractive therapeutic target
and underscores the importance of reevaluating the
indiscriminate use of EPO
in the treatment of anemia
associated with cancer
therapy.
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Duchenne muscular dystrophy (DMD) is a degenerative muscle wasting disease
caused by mutations in the
dystrophin gene. DMD has
a high incidence in all world
populations, due to the high
rate of new mutations in the
dystrophin gene. DMD patients show myofiber membrane instability from birth.
Muscle weakness usually
begins around age four followed by a gradual replacement of skeletal muscle with
fibrous and fatty tissue.1
Transforming growth
factor beta (TGF-ß) is a family of proteins secreted by
many cell types. These proteins regulate a variety of
cellular processes and have
been implicated in many
disease processes, including
DMD.2 For example, with
some vascular conditions,
such as pulmonary hypertension, TGF-ß1 has been
shown to stimulate excess
synthesis of extracellular
matrix proteins and inhibit
matrix degradation.3 Additionally, TGF-ß1 inhibits in
vitro myoblast proliferation
in some cultured muscle cell
lines and primary myogenic
cells.4 It also suppresses proliferation and delays muscle
regeneration in vivo.4 It has
been demonstrated that
TGF-ß1 secretion by C2C12
myoblasts leads to downregulation of myogenic proteins such as MyoD and
increased expression of fibrotic proteins.5
Insulin-like growth factor

binding protein 3 (IGFBP3)
has recently been shown to
interact with the TGF-ß
pathways. IGFBP3 has been
shown to suppress proliferation of various cell types by
blocking cell cycle and inducing apoptosis.6,7 Besides
their IGF-dependent mechanism of action, IGFBP3 may
affect cells by IGF-independent mechanisms including
binding to cell surface receptors, including the TGF-ß1
receptors.7-9 Recent studies
show that IGFBP3 is
upregulated in mid-to-late
stages of DMD. Currently,
research is being performed
to test the hypothesis that
TGF-ß1 pathways lead to
fibrosis and defects in
muscle regeneration, which,
in turn, leads to muscle wasting in later stages of DMD.
Also, there is ongoing research to identify downstream targets of TGF-ß1.
In this research, the effects of TGF-ß1 on C2C12
myoblast phenotype and
IGFBP3 expression were
studied. This preliminary
study stemmed from the
hypothesis that the inhibition of myogenesis/regeneration of dystrophin-deficient
muscle in later stages of
DMD is mediated, at least
in part, by IGFBP3.
This research used the
mouse myoblast cell line
C2C12. These cells have the
ability to become skeletal
muscle cells and are often
used in experiments looking
at myogenesis (skeletal

muscle development) and cell
differentiation. Bbecause
they are cells that are not
terminally differentiated, one
can see how external factors
affect the process of these
less mature cells becoming
more mature skeletal muscle
cells.
C2C12 cells were incubated in differentiation medium containing Dulbecco's
Modified Eagle's Medium
(DMEM), two percent fetal
bovine serum and penicillin/
streptomycin (1:100) to facilitate cell maturation with
and without TGF-ß1 for 72
hours. Cell differentiation
was inhibited in cells treated
with higher TGF-ß1 concentrations compared to cells
treated with lower TGF-ß1
concentrations or cells not
treated with TGF-ß1 at all. It
is likely that the exposure to
high concentrations of TGFß1 led to the downregulation
of myogenic proteins, such
as MyoD, and the
upregulation of fibrosis-related proteins, such as
fibronectin. As a result, cultures with a high concentration of TGF-ß1 showed
fewer myotubes (Figure 1).
In cultures with no TGFß1 and low concentrations of
TGF-ß1, the transition from
expression of myogenic proteins to fibrotic proteins
does not likely occur to the
extent as in cultures with
high concentrations of TGFß1. Thus, in cultures where
the frequency of myoblasts
was high, expression of the
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MyoD family of transcription factors was likely high,
leading to myogenic differentiation by expression of various muscle specific genes.10
An increase in IGFBP3
expression due to TGF-ß1
was previously shown in
various cells.11-13 Levels of
IGFBP3 and TGF-ß1 have
been shown to be higher in
patients in later stages of
DMD, and it was hypothesized that the muscle wasting and increased fibrosis
seen in later stages of DMD
was the result of TGF-ß1
pathways upregulating
IGFBP3. Our results, however, do not show a correlation between TGF-ß1 exposure and IGFBP3 expression
in C2C12 myoblasts. These
studies may need to be repeated with greater sample
size to confirm the results.
While TGF-ß1 and
IGFBP3 expression may not
be correlated in mouse
C2C12 myoblasts, it is possible that this relationship
does exist in other species,
including humans. Other cell
lines, particularly primary
cells, should be tested.
Studying the effects of molecular pathways, such as the
TGF-ß1 pathway, is important because it may eventually lead to a model for
DMD pathogenesis and uncover potential targets of
therapy for DMD and other
muscle wasting disorders.
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The difference could be in
an atom or two. When reading the structural maps of
proteins, a crystallographer
tries to accurately determine
the location of an amino
acid building block, side
chain or substrate molecule.
Within the limits of technology, the crystallographer
must carefully identify molecules, attempt to discover
the order of nature and perhaps learn why a potential
drug may be able to fight
cancer.
Glycosylation is the “ornamenting” process of all cells.
Tumor cells that display specific sugar “ornaments” are
directly involved in the metastasis of certain lung and
colon cancers. Preliminary
results from a mapping study
at the National Cancer
Institute suggest that a
unique disaccharide compound is capable of inhibiting
glycosylation
activity of
1,4-galactosyl-transferase.1 Experimental
studies performed by
Brown et al
have shown
positive signs
of the

compound’s antimetastatic
potential.2
To see how the molecule

A crystallographer
must carefully identify molecules, attempt to discover
the order of nature
and perhaps learn
why a potential
drug may be able to
fight cancer.
fits into the substrate binding “pocket” of 1,4galactosyltransferase, forming the crystal structure of
the enzyme-substrate complex was vital. High-quality

crystals were obtained with
the human mutant enzyme,
Met344His-Gal-T1,3 bound
to the acceptor substrate,
GlcNAcß1,3Galß-Onaphthalenemethanol (the
disaccharide moeity), after
purifying the enzyme to
about 99 percent homogeneity. Figure 1 shows crystals
of the mutant
galactosyltransferase in complex with the disaccharide
obtained after 48 hours.
I began to learn the steps
involved in protein crystallography as part of my summer internship in Dr.
Pradman Qasba’s lab at the
National Cancer Institute in
Frederick, MD, under Dr.
Boopathy Ramakrishnan’s
mentorship.
I learned how to crystal-

Figure 1. Crystals of
the mutant
galactosyltransferase
in complex with the
disaccharide
obtained after 48
hours. (Courtesy of
Najma Khorrami)
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lize the enzyme, given a relatively complex recipe from
Dr. Ramakrishnan. In one of
my first attempts to crystallize the disaccharide substrate with the enzyme, I
plated a set of 18 wells with
microliter-sized protein
droplets and waited for crystals to appear.
After waiting 48 hours,
using the hanging drop vapor
diffusion method (in which
the basis for crystallization is
a concentration gradient
between the droplet and solvent within the same well), I
noticed a large diamondshaped crystal in a droplet
under the microscope. While
some parts of the crystallization process were tedious,
others made the wait and the
work seem near trivial.
Preliminary x-ray results
showed that the disaccharide
compound bound to the
substrate site with equal or
higher affinity than a natural
trisaccharide molecule analyzed previously.4 The results
support the hypothesis that
the disaccharide “decoy” is
able to bind tightly to the
molecule and divert
glycosylation of natural substrates and ultimately inhibit
tumor cells from binding to
blood platelets, which enables the cancer to metastasize.
The normal glycosylation
process is close to, but not
exactly, what happens when
the “decoy” is in place.
Here, a dangling naphthalene
molecule, which is bound to
the disaccharide, conforms
to the substrate binding site
similarly to the third sugar
molecule in the natural
trisaccharide. Eventually,
“cloaking” occurs with cells
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missing the natural trisaccharide, triggering hematogenous metastasis.
Jillian R. Brown, PhD, of
the University of California
will continue experimental
studies using the “decoy”
disaccharide compound. Her

hibit metastasis in rats by
limiting the ability of tumor
cells to proliferate in the
body by binding to blood
platelets via signature sugar
chains on cell membranes.
“The idea of compounds
acting as ‘primers’ by decoy-

Figure 2. Crystals of the
mutant
galactosyltransferase in
complex with the
disaccharide were
obtained after 48 hours
(Courtesy of Najma
Khorrami)

clinical-focused research on
the molecule’s ability to target colon and lung cancer
cell metastasis, both in vitro
and in vivo, has lasted close
to five years. She understands the important benefits
of a potential antimetastatic
drug if it entered the market.
“Nothing clinically useful
is available for the treatment
of metastasis,” says Dr.
Brown. “At the molecular
level, there are lots of hypotheses but little is known
(mechanistically).” The studies conducted in the laboratory of Jeffrey Esko, PhD at
the University of California,
have examined the
disaccharide’s ability to in-

ing the synthesis of endogenous glycoconjugates has
been ongoing in our lab for
many years. The first identification was in an experiment with U937, a human
lymphoma cell line,” says
Dr. Brown. “Now, the disaccharide is being developed
further and will enter preclinical trials as an
antimetastatic agent.”
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Institute Student Poster Collaboration, 2006.
2. Brown JR, Fuster MM, Fuster
RL, Varki N, Glass CA, Esko
JD. A Dissacharide-Based
Inhibitor of Glycosylation
Attenuates Metastatic Tumor
Cell Dissemination. Clincal
Cancer Research. 2006;12(9):
2894-2091.
3. Ramakrishnan B, Boeggeman
E, Qasba P. Effect of the
Met344His mutation on the
conformational dynamics of
bovine beta-1,4galactosyltransferase: crystal
structure of the Met344His
mutant in complex with
chitobiose. Biochemistry.
2004;43(39):12513-12522.
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Planning Ahead ...
Fusion is the annual publication of the GW chapter of The Beaumont Society
to showcase student achievements in the fields of biomedical research,
public health research, clinical research and international health related
travel experiences.
Submissions for next year’s issue of the journal will be accepted
beginning September 2007 from the Class of 2010 as well as the
incoming Class of 2011. More information about the submission process
will be provided during the summer of 2007. If students have any
questions or comments, contact the Beaumont Society at gwbeaumont@gmail.com.
Contributions to the publishing costs of this journal are appreciated. If you would like to make a
donation, please contact us at gwbeaumont@gmail.com. All proceeds will go toward the publishing
costs for next year’s journal for next year.
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Beaumont
Leaders
2006-2007 officers of the William
H. Beaumont Society at The George
Washington University include, top
row, from left: Andrew Lerner,
president; Vivek Patil, co-vice
president; Steven Kardos,
secretary; and Rahul Arya, research
journal chair; seated, from left:
Rasha Al-Bawardi, co-vice
president; Jennifer Goldstein,
research day coordinator; and Ajay
Wadgaonkar, MSI student
representative.

The William H. Beaumont Society is an honorary research society of medical students that
was established in 1935 in honor of Dr. William Beaumont, a pioneer in physiology
research. The organization seeks to foster a continuing interest in biomedical research and to
promote its value in the practice of medicine. As a part of this mission, the Society integrates
current research topics with the curriculum, develops a research journal showcasing GW student research, makes available information on research opportunities and seminars throughout
the area, including the William T. Gill Summer Fellowship for GW medical students, and highlights student and faculty research accomplishments at the annual GW Research Day.
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